Mammary Cell News 10.04 February 1, 2018 | |
| |
TOP STORYScientists performed phosphoproteomic analysis on untransformed mammary epithelial cells that were stimulated in culture with epidermal growth factor (EGF). They identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. [Sci Signal] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors observed that the expression level of annexin A3 (ANXA3) was significantly upregulated in breast cancer tissues. ANXA3 knockdown inhibited cell invasion but promoted cell proliferation in both in vitro and in vivo assays. [Cell Death Dis] Full Article Investigators demonstrated that atypical ductal hyperplasia-associated fibroblasts are one kind of activated fibroblasts, and stimulate cell growth and polarity change of epithelium-like tumor cell MCF-7 as cancer-associated fibroblast-like fibroblasts. [Cell Death Dis] Full Article Integrin-uPAR Signaling Leads to FRA-1 Phosphorylation and Enhanced Breast Cancer Invasion While characterizing five breast cancer cell lines derived from primary human breast tumors, scientists identified BRC-31 as a novel basal-like cell model that expressed elevated Fos-related antigen 1 (FRA-1) levels. They interrogated the functional contribution of FRA-1 and an upstream signaling axis in breast cancer cell invasion. [Breast Cancer Res] Full Article The authors characterized a novel long non-coding RNA (lncRNA), MANCR, which is upregulated in breast cancer patient specimens and cells. Depletion of MANCR in triple-negative breast cancer cells significantly decreased cell proliferation and viability, with concomitant increases in DNA damage. [Mol Cancer Res] Abstract AmotP130 Regulates Rho GTPase and Decreases Breast Cancer Cell Mobility Scientists investigated the role of AmotP130 in the reorganization of the actin cytoskeleton and the changes of morphology in breast cancer cells through the Rho pathway that influences the invasion and migration of cells. [J Cell Mol Med] Full Article miR-539 Acts as a Tumor Suppressor by Targeting Epidermal Growth Factor Receptor in Breast Cancer Researchers found that expression of miR-539 was markedly down-regulated in breast cancer tissues and cell lines compared with that in paired adjacent normal tissues and normal cell lines. [Sci Rep] Full Article Omega-3 Docosahexaenoic Acid Induces Pyroptosis Cell Death in Triple-Negative Breast Cancer Cells Scientists investigated the role of docosahexaenoic acid (DHA) in triggering pyroptosis activation in breast cancer cells. MDA-MB-231 breast cancer cells were supplemented with DHA and inflammation cell death was analyzed. [Sci Rep] Full Article By analyzing different estrogen receptor-α (ER-α)-positive and ER-α-negative breast cancer cell lines, the authors defined the role of CCN5 in the leptin-mediated regulation of growth and invasive capacity. [BMC Cancer] Full Article Investigators report that miR-130a is a novel FOSL1 targeting miRNA. Using gene expression microarray analysis, they found that FOSL1 is among the most up-regulated genes in cells transfected with miR-130a inhibitors. [J Cell Biochem] Abstract | |
| |
REVIEWSAnti-Insulin-Like Growth Factor Therapy in Breast Cancer The author evaluates the rationale for type I insulin-like growth factor receptor inhibition, discusses results of the clinical trials, and suggests a path forward. [J Mol Endocrinol] Abstract | Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSSeattle Genetics, Inc. and Cascadian Therapeutics, Inc. announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. [Seattle Genetics, Inc.] Press Release PharmAbcine Inc. announced it has entered into a collaborative agreement with Merck & Co., Inc. (MSD), through a subsidiary, to evaluate PharmAbcine’s anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-programmed death receptor-1 therapy, KEYTRUDA®, in patients with recurrent glioblastoma multiforme and metastatic triple-negative breast cancer. [PharmAbcine Inc. (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSIndian Science Budget Fails to Impress — Despite Funding Boost Ministers announce detailed spending plans, with focus on artificial intelligence and cyber systems. [Nature News] Editorial Computer Scientist to Lead French Research Giant; Interim Head Leaves Amid Misconduct Allegations Computer scientist Antoine Petit, 57, is the new head of Europe’s largest research organization. There was an unusual twist to Petit’s appointment, however. A week before the official procedure ended, the French government named Petit interim president of the National Center for Scientific Research, a position that had been held by cell biologist Anne Peyroche since Fuchs’s departure. [ScienceInsider] Editorial
| |
EVENTSNEW 8th EACR-OECI Joint Course: Molecular Pathology Approach to Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Fellow – Breast Immunology (Dana-Farber Cancer Institute) Postdoctoral Fellow – Cancer Biology (University of Arkansas for Medical Science) Postdoctoral Research Associate – Cancer Biology (King’s College London) Postdoctoral Researcher – Development of Novel Cancer Therapies (University of Oxford) Cancer Bioinformatician – Breast Cancer Research (The Institute of Cancer Research) Scientific Officer – Breast Cancer Research (The Institute of Cancer Research) Higher Scientific Officer – Breast Cancer Research (The Institute of Cancer Research) Postdoctoral Associate – Breast Cancer Research (University of Miami) Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|